Company intelligence / Profile preview

Translational Sciences, Inc.

Paradise Valley, Arizona, United States

Ownership: Private
Development stage: Phase 2

Overview

Their lead drug TS23 shows promise in dissolving blood clots and aneurisms that could cause strokes. The company signed an exclusive licensing agreement with CSL, a leading global biotechnology company, for TS23.

Therapeutic areas: HematologyCardiovascular
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

TS23

Partnerships

CSL (exclusive licensing agreement for TS23)

Beyond the preview

Go deeper on Translational Sciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Translational Sciences, Inc..

Explore the full profile